An & An Global is a London-based biotech company with a primary aim to develop tomorrow's biotechnology today. We employ cutting-edge technology and biomedical research to resolve existing and upcoming challenges in healthcare, disease diagnosis, medication and treatment development. Our passion is to promote the production of affordable medicinesPHARMACOGENOMIC MODULES One of the key focal areas of An & An Global is developing pharmacogenomic modules which will enable Doctors to prescribe medication to patients based on their genetic outlook, hence minimising side-effects as much as possible. Our current focus is on beta-blocker anti-hypertensives and anti-cholesterol statins. A research conducted in the UK on 165,000 patients and reported on the BBC highlighted limited effectiveness of statins in 50% of subjects treated. With gene-specific prescriptions of statins, this percentage could be increased significantly. COVID-19 IN-STORE SOCIAL-DISTANCING As COVID-19 wanes down, the world has to adopt to the new normal which involves a life of social distancing especially in commercial outlets. We are working with our stakeholders to develop a massive software solution which we are very excited about. This new venture is proceeding rapidly hence we are keen to hear from investors and interested collaborators.GLOBAL PRODUCTION OF HIGH-QUALITY AFFORDABLE MEDICINE AND NATURAL WELLNESS PRODUCTSWe have a strong belief that high quality medication should be affordable especially for low income families in developing countries. This can be made possible via cutting-edge technology and know-how. An & An Global is passionate about using our technical and financial resources to help in the production of affordable medicines and natural wellness products globally currently focussing on Africa, Asia and Middle East with special interest in anti-malaria medication.